Please ensure Javascript is enabled for purposes of website accessibility

5 Reasons This Growth Stock Is Up 23% So Far in 2019

By Lee Samaha - Apr 27, 2019 at 6:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Danaher's management continues to transform the conglomerate, and the GE Biopharma deal looks like an even better value after a recent disclosure.

It's been a good year for investors in Danaher (DHR 1.05%), with the conglomerate's stock up nearly 23% in 2019 at the time of this writing. That gain is outpacing the S&P 500, and given the trends in recent earnings, it could continue. Let's look at the five reasons Danaher's stock is outperforming and what investors can expect in the future.

1. It has made growth-enhancing acquisitions

For obvious reasons, Danaher's former CEO Larry Culp is attracting more media attention than current CEO Tom Joyce. Culp, now the CEO of General Electric (GE 2.37%), is engaged in turning around the ailing industrial giant. Meanwhile, Joyce continues to refocus Danaher toward life sciences and diagnostics with the aggressive deal to buy the biopharma business of GE Life Sciences for a net purchase price of $20 billion.

A bull in front of a stock chart

Image source: Getty Images.

The deal makes sense for both parties. Danaher is buying growth, and GE gets cash with which to pay down debt. But given what Danaher's CFO Matthew McGrew disclosed on the recent earnings call, it looks even better. At the time of the deal announcement, Danaher's management claimed that the deal price represented 17 times expected 2019 EBITDA.  

That looks like a rich but fair valuation for a growth business with 75% of its revenue recurring -- implying a highly reliable income stream. But McGrew's recent disclosure that GE Biopharma is generating about $1 billion or so in free cash flow (FCF) will be music to the ears of Danaher's shareholders.

In a nutshell, Danaher is buying a growth business with highly reliable earnings for just 20 times FCF -- a discount to the 24 times FCF multiple that Danaher traded on before the deal announcement. It's a very good deal for Danaher, but for GE investors it's a bit concerning that the company is divesting a business generating around a third of the FCF from its healthcare segment.

2. Its dental spin-off receives good news

Acquiring GE Biopharma isn't the only corporate action being taken by Danaher this year; the company plans to spin off its dental business in the second half of 2019. It's been underperforming in terms of revenue growth, but the latest news suggests signs of improvement -- a timely development for shareholders, because they should want the dental business to start life as an independent company on a strong note.

As you can see below, the dental segment looks like it has returned to at least low-single-digit core revenue growth.

Danaher year over year core revenue growth

Data source: Danaher Corporation presentations. 

3. All segments are performing well

As you can see above, Danaher has reported mid-single-digit core revenue growth for six quarters in a row. Moreover, Joyce said, "Our growth was broad-based, with all four segments delivering better than expected results, and we continue to see healthy conditions across our major end markets."

Danaher's guidance assumes 4% core revenue growth in 2019. But with growth of 5.5% in the first quarter and management guiding toward 4% to 5% core revenue growth in the second quarter, that original 2019 guidance looks conservative. The subject came up on the earnings call, and Joyce promised investors an update in July -- something to look out for.

4. Don't worry about China

It's no secret that China's overall growth is slowing in 2019. Throw in the possibility of further friction from ongoing trade disputes, and the market has reason to be concerned by a possible impact on companies exporting to China.

That said, it's clearly a question of specific industry exposure. And fortunately, Danaher is well positioned for growth. As Joyce outlined, this was the ninth consecutive quarter of double-digit growth across all four segments in China.  He went on to state that the only potential softness in growth he saw in the second half was due to coming up against very strong growth in the water quality business in the previous year.  Life sciences, diagnostics, dental, and water quality are relatively better businesses to be exposed to, versus, say, automotive or consumer electronics in China in 2019.

5. Playing defense in 2019

With a market worried about slowing global growth and a reduction in U.S. industrial production growth, it's understandable if investors should want to avoid some of the more cyclical stocks in the market. In this context, Danaher's mix of defensive businesses -- plus the addition of GE biopharma -- mean the stock is likely to be favored by investors looking for relative security.

Looking ahead

The GE biopharma deal and the dental spin-off are obviously the key corporate events of 2019, but investors shouldn't lose sight of the fact that Danaher appears to be tracking ahead of its expectations for the current year. With ongoing execution in the current vein, Danaher's stock can continue to do very well this year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Danaher Corporation Stock Quote
Danaher Corporation
$248.97 (1.05%) $2.60
General Electric Company Stock Quote
General Electric Company
$76.40 (2.37%) $1.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.